Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

Fig. 2

Concentration–time profile following a single IV dose of MEDI3902 500 mg and 1500 mg in serum (a) and endotracheal aspirate (b) PK geometric mean profile. ETA = endotracheal aspirate. IV = intravenous. LLOQ = lower limit of quantification. PK = pharmacokinetic. SE = standard error

Back to article page

Critical Care

ISSN: 1364-8535